On July 2, 2020, the National Medical Product Administration (NMPA) and the National Health Commission (NHC) published the 2020 Edition of the Pharmacopoeia of the People's Republic of China, which came into force on December 30, 2020. All pharmaceutical products with China's marketing authorization shall meet the technical requirements of dosage forms, test methods, guidelines, etc., in the Chinese Pharmacopoeia since the day of implementation.
Related:
China Issues Corrigenda for the Chinese Pharmacopoeia (ChP) 2020
